801 results on '"Castellucci, Paolo"'
Search Results
2. Potential Clinical Applications of Dedicated Prostate Positron Emission Tomography
3. Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?
4. Radiolabeled FAP inhibitors as new pantumoral radiopharmaceuticals for PET imaging: a pictorial essay
5. Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial
6. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence
7. Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer.
8. Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection
9. MP74-18 PSMA EXPRESSION IN HIGH-RISK PROSTATE CANCER: HEAD-TO-HEAD COMPARISON OF PREOPERATIVE PSMA-PET FEATURES AND IMMUNOHISTOCHEMISTRY ANALYSIS OF BIOPTIC CORES AND WHOLE MOUNT SPECIMEN
10. PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget
11. Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT
12. Brain 18F-Fluorodeoxyglucose (FDG) PET
13. Gynecological Malignancies
14. Infection and Inflammation
15. Malignancies of the Upper Gastrointestinal Tract
16. Breast Cancer
17. Head and Neck Malignancies
18. Malignancies in Hematology
19. Malignancies in Dermatology
20. Thoracic Malignancies
21. Malignancy in Orthopedics
22. Malignancies of Lower Gastroenterological Tract
23. Cancers of Unknown Origin
24. Premises to PET/CT with FDG in Oncology
25. Urological Malignancies
26. Normal Distribution, Variants, and Artifacts (Versus Pathological Uptake in Malignant and Benign Diseases)
27. High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results.
28. Multiparametric Whole-Body MRI: A Game Changer in Metastatic Prostate Cancer.
29. Complete metabolic response after Partially Ablative Radiotherapy (PAR) for bulky retroperitoneal liposarcoma: A case report
30. Theragnostic: radiopharmaceuticals and nuclear medicine as viewed through Hegel’s eyes
31. A case of [68Ga]Ga-FAPI-46-avid and [18F]F-FDG-negative COVID-19 pneumonia sequelae
32. Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database
33. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer
34. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer
35. Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders
36. Potential Clinical Applications of Dedicated Prostate Positron Emission Tomography
37. Nuclear Medicine Imaging of Prostate Cancer in the Elderly
38. Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer
39. Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography
40. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy
41. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy
42. 1151: Role of 68Ga-PSMA PET/CT before early salvage radiotherapy in prostate carcinoma.
43. 1107: Sarcopenic obesity is a key prognostic factor in advanced cervical cancer: an observational study
44. 1096: Classical prognostic factors outperform SUV-max in LACC: an observational study
45. Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography
46. Molecular Imaging and Precision Medicine in Prostate Cancer
47. Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL
48. Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer
49. The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals
50. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.